What are the treatment options for common gastro issues such as Gastroesophageal Reflux Disease (GERD), Irritable Bowel Syndrome (IBS), and Inflammatory Bowel Disease (IBD)?

Treatment of Common Gastrointestinal Issues

GERD Management

For patients with typical GERD symptoms (heartburn, regurgitation) without alarm signs, initiate a 4-8 week trial of once-daily proton pump inhibitor (PPI) therapy before meals, which is both safe and effective as first-line treatment. 1

Initial Approach to GERD

• Provide standardized education on GERD mechanisms, weight management, lifestyle modifications, and the brain-gut axis relationship to all patients 1
• Emphasize the safety of PPIs to address common patient concerns about long-term use 1
• Start with omeprazole 20 mg or lansoprazole 30 mg once daily, taken 30-60 minutes before the first meal 2, 3
• If inadequate response after 4-8 weeks, escalate to twice-daily dosing or switch to a more potent acid suppressive agent 1

Lifestyle Modifications with Proven Efficacy

• Weight loss improves both pH profiles and symptoms (this has the strongest evidence among lifestyle interventions) 4
• Elevate the head of bed by 6-8 inches to improve esophageal acid exposure time 4
• Avoid late-evening meals within 2-3 hours of bedtime 1

Critical Pitfall: Despite widespread recommendations, there is no published evidence that tobacco cessation, alcohol cessation, or specific dietary restrictions (coffee, chocolate, spicy foods) improve GERD symptoms or esophageal pH profiles 4. However, these may still be considered on an individual basis if patients identify them as triggers.

Long-Term Management Strategy

• For patients who respond to PPI therapy without erosive disease on endoscopy: wean to the lowest effective dose or on-demand therapy with H2-receptor antagonists/antacids 1
• For patients with erosive esophagitis (Los Angeles grade B or higher) or Barrett's esophagus: continue PPI indefinitely 1
• For severe GERD phenotype (Los Angeles grade C/D esophagitis, acid exposure time >12%, or large hiatal hernia): consider long-term PPI or anti-reflux procedures 1

When to Escalate Beyond Medical Therapy

• Perform upper endoscopy if alarm symptoms present (dysphagia, weight loss, GI bleeding), inadequate response to PPI, or isolated extra-esophageal symptoms 1
• Consider 24-hour pH-impedance monitoring ON PPI for patients with persistent symptoms despite optimized therapy, particularly those with belching and regurgitation 1
• Add cognitive behavioral therapy, gut-directed hypnotherapy, or neuromodulators for refractory symptoms 1

Surgical Options for Refractory GERD

• Laparoscopic fundoplication is effective in non-obese patients with proven GERD after appropriate esophageal physiologic testing 1
• Magnetic sphincter augmentation combined with crural repair is an option for patients with hiatal hernia 1
• Transoral incisionless fundoplication is effective in carefully selected patients without hiatal hernia 1
• Roux-en-Y gastric bypass is the preferred anti-reflux intervention in obese patients, while sleeve gastrectomy may worsen GERD 1

---

Irritable Bowel Syndrome (IBS) Management

Begin with soluble fiber supplementation (ispaghula/psyllium 3-4 g/day, gradually increased) and regular physical exercise for all IBS patients, then escalate to tricyclic antidepressants (amitriptyline 10 mg nightly, titrated to 30-50 mg) for persistent global symptoms and abdominal pain. 1, 5, 6

First-Line Treatment Approach

• Recommend regular physical exercise to all IBS patients as foundational therapy with minimal risk 5, 6
• Provide dietary counseling by a trained dietitian, starting with identification of trigger foods 5, 6
• Initiate soluble fiber (ispaghula/psyllium) at 3-4 g/day, building up gradually to avoid bloating 1, 5
• Avoid insoluble fiber (wheat bran) as it consistently worsens symptoms 5
• Consider a 12-week trial of probiotics for global symptoms and abdominal pain; discontinue if no improvement 5, 6

Subtype-Specific Pharmacological Management

IBS with Diarrhea (IBS-D)

• Loperamide 2-4 mg up to four times daily is the most effective first-line pharmacological treatment for reducing stool frequency, urgency, and fecal soiling 5, 6
• Consider bile acid sequestrants (cholestyramine) for the approximately 10% of IBS-D patients with bile salt malabsorption 6
• Rifaximin (non-absorbable antibiotic) is effective as second-line therapy, though its effect on abdominal pain is limited 5
• 5-HT3 receptor antagonists (ondansetron 4-8 mg) are effective second-line options for refractory diarrhea 5

IBS with Constipation (IBS-C)

• Start with polyethylene glycol (osmotic laxative), titrating dose according to symptoms 5
• Increase dietary fiber or use ispaghula/psyllium supplementation 1, 5
• Linaclotide is the most effective secretagogue for IBS-C and should be the preferred second-line agent when first-line therapies fail 5
• Lubiprostone is an alternative secretagogue if linaclotide is not tolerated 5

Critical Pitfall: Avoid anticholinergic antispasmodics (like dicyclomine) in IBS-C patients, as they reduce intestinal motility and enhance water reabsorption, which exacerbates constipation 5. These agents are only appropriate for IBS-D or IBS with mixed symptoms.

Second-Line Neuromodulator Therapy

• Tricyclic antidepressants (TCAs) are the most effective treatment for global symptoms and abdominal pain across all IBS subtypes 1, 5, 6
• Start amitriptyline 10 mg once daily at bedtime, titrate slowly (by 10 mg/week) to 30-50 mg daily 5, 6
• Continue TCAs for at least 6 months if symptomatic response occurs 5, 6
• Use TCAs cautiously in IBS-C and ensure adequate laxative therapy is in place, as they may worsen constipation 5
• Selective serotonin reuptake inhibitors (SSRIs) may be effective as second-line neuromodulators when TCAs are not tolerated 1, 5

Antispasmodic Therapy

• Certain antispasmodics with anticholinergic properties are effective for abdominal pain and global symptoms, though they cause dry mouth, visual disturbance, and dizziness 1, 5, 6
• Peppermint oil may be useful as an antiespasmódico with fewer side effects 5

Psychological Therapies for Refractory Symptoms

• IBS-specific cognitive behavioral therapy and gut-directed hypnotherapy should be considered when symptoms persist despite 12 months of pharmacological treatment 1, 5, 6
• These brain-gut behavior therapies differ from standard psychological therapies targeting depression and anxiety alone 6
• Dynamic (interpersonal) psychotherapy is beneficial for patients who relate symptom exacerbations to stressors or have associated anxiety/depression 5
• Stress management/relaxation techniques are particularly beneficial for patients with waxing and waning symptoms 5

Treatment Monitoring

• Review treatment efficacy after 3 months and discontinue ineffective medications 5, 6
• Recognize that symptoms relapse and remit over time, requiring periodic adjustment of treatment strategy 6
• Avoid extensive testing once IBS diagnosis is established, as this increases healthcare costs without improving outcomes 6

Critical Pitfall: Never prescribe opiates for chronic abdominal pain in IBS, as they increase risk of overdose and cause opioid-induced gastrointestinal side effects 6.

---

Inflammatory Bowel Disease (IBD) Management

For active Crohn's disease or ulcerative colitis, initiate corticosteroids for acute flares, then transition to immunomodulation with azathioprine, mercaptopurine, or methotrexate for maintenance therapy to prevent relapse. 1

Acute Disease Management

• Corticosteroids are the primary treatment for acute flares of both Crohn's disease and ulcerative colitis 1
• For patients requiring surgery, subtotal colectomy leaving a long rectal stump is the procedure of choice in acute fulminant UC or CD 1

Maintenance Therapy to Prevent Relapse

• Immunomodulation with azathioprine, mercaptopurine, or methotrexate should be initiated if steroids cannot be withdrawn without disease deterioration 1
• Methotrexate IM 25 mg weekly for up to 16 weeks, followed by 15 mg weekly, is effective for chronic active Crohn's disease 1
• Oral methotrexate dosing is effective for many patients 1
• Monitor full blood count within 4 weeks of starting azathioprine/mercaptopurine, then every 6-12 weeks to detect neutropenia 1

Biologic Therapy for Refractory Disease

• Infliximab (5 mg/kg) should be reserved for patients with moderate to severe Crohn's disease who are refractory to or intolerant of steroids, mesalazine, azathioprine/mercaptopurine, and methotrexate, and where surgery is considered inappropriate 1

Surgical Considerations

• Surgery in Crohn's disease should only be undertaken for symptomatic rather than asymptomatic, radiologically identified disease 1
• Resections in Crohn's disease should be limited to macroscopic disease 1
• Primary anastomosis should not be performed in the presence of sepsis and malnutrition 1
• Patients requiring elective surgery for UC should be counseled regarding all surgical options, including ileo-anal pouch where appropriate 1

Managing Functional Symptoms in IBD Patients with Quiescent Disease

• Use fecal calprotectin and endoscopy with biopsy to distinguish active inflammation from functional symptoms 6
• Apply the same dietary and psychological interventions as for primary IBS, though evidence is less robust in IBD populations 6
• TCAs have demonstrated clinically relevant benefit in retrospective cohort studies of IBD patients with functional symptoms 6
• Avoid opiates particularly in IBD patients with IBS symptoms after remission of acute inflammation 6

Pain Management in IBD

• Abdominal pain has many potential mechanisms including acute/subacute obstruction, serosal and mucosal inflammation, visceral hypersensitivity, and secondary IBS 1
• Where possible, treat the underlying cause including corticosteroids and treatment of associated IBS 1
• Where non-specific pain relief is needed, tramadol (an opioid with less effect on motility) may help 1

Surveillance for Complications

• The value of surveillance colonoscopy in UC for colorectal carcinoma remains debated but should be discussed with individual patients regarding their risk 1